2nd LNP Characterization and Analytical Development Summit

Turbocharged by increased LNP pipeline development and technological advancements with SPARTA biodiscovery raising $4.3m for their characterization technology, UPENN engineers developing CAR-T therapies, and Genevant securing a $114m deal with Tome. As the industry places a greater emphasis on later-phase assets, understanding the intricacies of LNPs and investing in analytical assays are becoming essential for ensuring market confidence.

Join a community of 60+ analytical, potency, and characterization experts at the 2nd Characterization and Analytical Development Summit this November to enable you to:

- Evaluate different characterization techniques for early-stage development to select the most robust methods: fluorescence, chromatography, imaging, and cryo-EM

- Conduct biophysical characterization to comprehend LNP in vivo and in vitro behavior

- Analyze complex LNP drug products with targeting moieties and multiple payloads across oligonucleotides, CRISPR-Cas9, RNAs, and beyond

- Develop potency assays for safety and quality assessments, employing gold standard techniques and validated assays

- Explore robustly tested critical quality attributes and release criteria for confidence in pipeline development and regulatory submission

As the only summit dedicated to LNP drug product characterization and analytical development, join us this November to unite the industry and advance LNP analytics, deriving practical applications to drive quality, efficacious LNPs.

URLs:
Website: https://go.evvnt.com/2555692-0?pid=176 
Tickets: https://go.evvnt.com/2555692-2?pid=176 
Brochure: https://go.evvnt.com/2555692-3?pid=176 

Time: 8:00 AM - 3:30 PM

Prices:
Conference Only - Drug Developer: USD 2999.00,
Conference Only - Solution Provider: USD 3699.00,
Conference Only - Academics: USD 2599.00

Speakers: Benjamin Hall, Senior Scientist - Analytical Development, Tessera Therapeutics, Carlo Zambonelli PhD, Independent Expert, Caterina Minelli, Science Area Leader. National Physical Laboratory, Chris Broomell, Head of Analytical Development, Omega Therapeutics, Heinrich Haas, Chief Technology Officer, NeoVac, Matthew Eastwood, Scientist II, Novo Nordisk, Mohit Gupta, Senior Scientist, Tessera Therapeutics, Prasad Sarangapani, Principal Scientist - Analytics, Verve Therapeutics, Ronald Toth, Associate Director, Characterization, Sanofi, Sean Bedingfield, Senior Advisor, Eli Lilly and Co., Shijia Tang, Principal Scientist, Genentech, Sixuan Li, Postdoctoral Research Associate, John Hopkins, Swarnendu Kaviraj, Associate Director - R AND D, Gennova Biopharma, Valerie Nelson, Senior Research Associate I, Analytical R AND D, Beam Therapeutics, Yi Pu, Group Head, Prime Medicine, Yun Liu, DMPK Project Representative, Moderna, Zhinan Xia, Chief Scientific Officer, Abimmmune Bio